Hướng dẫn sử dụng thuốc kháng đông phòng ngừa thuyên tắc do huyết khối trong rung nhĩ không do bệnh lý van tim
Tóm tắt
Hướng dẫn sử dụng thuốc kháng đông phòng ngừa thuyên tắc do huyết khối trong rung nhĩ không do bệnh lý van timTài liệu tham khảo
1. Connolly et al, N Engl J Med 2009; 361:1139-51
2. Brunton.L et al : Goodman and Gilman’s Manual of Pharmacology and Therapeutics. 2008:959.
3. Opie.L.H: drugs for the Heart. Sauders, 8th.2013 : 275-319
4. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulations in patients with non-valvular atrial fibrillation. Europace (2013) 15, 625-651.
5. Patel et al, N Engl J Med 2011;365:883-91
6. You.JJ et al: Antithrombotic therapt for AF : ACCP 2012:e531S-e569S.
7. ACC/AHA/ESC Guidelines for Mangement of Patients with Atrial Fibrillation.JACC Vol 38, No 4, 2006:e149-246
8. Jeffrey E.Olgin and Douglas P.Zipes: Specific Arrhythmias : Dignosis and treatment. In Eugene Brauwald, Douglas P.Zipes, Peter Libby : Heart Disease 9th.W.B Saunders Company, 2012: 816-819.
9. Eric N.prystowsky : A symposium : Atrial Fibrillation : Advances for the new millennium.AJC vol 85 May 25, 2000: 1D-45D.
10. Lane DA, Lip GYH. Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in non-valvular atrial fibrillation. Circulation 2012:126:860-865.
11. Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, Schotten U, Wegscheider K, Boriani G, Brandes A, Ezekowitz M, Diener H, Haegeli L, Heidbuchel H, Lane D, Mont L, Willems S, Dorian P, Aunes- Jansson M,Blomstrom-Lundqvist C, Borentain M, Breitenstein S, Brueckmann M, Cater N, Clemens A, Dobrev D, Dubệnh nhâner S, Edvardsson NG, Friberg L, Goette A, Gulizia M, Hatala R, Horwood J, Szumowski L, Kappenberger L, Kautzner J, Leute A, Lobban T, Meyer R, Millerhagen J, Morgan J, Muenzel F, Nabauer M, Baertels C, Oeff M, Paar D, Polifka J, Ravens U, Rosin L, Stegink W, Steinbeck G, Vardas P, Vincent A, Walter M, Breithardt G, Camm AJ. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. Europace 2012;14:8-27.
12. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH; ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120-129.
13. Binici Z, Intzilakis T, Nielsen OW, Kober L, Sajadieh A. Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. Circulation 2010;121:1904-1911.
14. Fitzmaurice DA, Hobbs FD, Jowett S, Mant J, Murray ET, Holder R, Raftery JP, Bryan S, Davies M, Lip GY, Allan TF. Screening vs. routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. Br Med J 2007;335:383.
15. Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, Raferty J, Davies M, Lip G. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) vs. routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess 2005;9:iii-iv, ix-x, 1-74.
16. Camm.J et al: 2012 focused update of the ESC guidelines for management of AF.European Heart Jourung nhĩal (2012) 33, 2719-2747
17. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
18. EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: 2013 executive summary
19. De Caterina R, Husted S, Wallentin L, Andreotti F, Arung nhĩesen H, Bachmann F,Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J,Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI; Coordinating Committee.New oral anticoagulants in atrial fibrillation and acute coronary syndromes:ESC Working Group on Thrombosis—Task Force on Anticoagulants in HeartDisease position paper. J Am Coll Cardiol 2012;59:1413-1425.
20. Wolf PA, Benjamin EJ, Belanger AJ, et al. Secular trends in the prevalence of atrial fibrillation: The FraminghamStudy. Am Heart J. 1996;131:790-5.
21. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for theManagement of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-429.
22. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications forrhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA)Study. JAMA. 2001;285:2370-5.
23. McManus DD, Rienstra M, Benjamin EJ. An update on the prognosis of patients with atrial fibrillation. Circulation. 2012;126:e143-e146.
24. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the FraminghamHeart Study. Circulation. 2004;110:1042-6.
25. Alonso A, Agarwal SK, Soliman EZ, et al. Incidence of atrial fibrillation in whites and African-Americans: theAtherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2009;158:111-7.
26. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrialfibrillation: population-based estimates. Am J Cardiol. 1998;82:2N-9N.
27. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The FraminghamStudy. Arch Interung nhĩ Med. 1987;147:1561-4.
28. Miller PS, Andersson FL, Kalra L. Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated? Stroke. 2005;36:360-6.
29. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Interung nhĩ Med. 2007;146:857-67.
30. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel userfriendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest 2010; March 18 [Epub ahead of print]
31. van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran, Am J Med 2012;125:417-20.
32. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, singlecentre study. Clin Pharmacokinet 2010;49:259-68.
33. Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N et al. Effects ofrenal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban,an oral, direct Factor Xa inhibitor. Brit J Clin Pharmacol 2010;70:703-12.
34. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S et al. Periprocedural bleeding and hromboembolic events with dabigatran compared to warfarin: results from the RE-LY Randomized Trial. Circulation 2012;126:343-8.
